	US 12,447,130 B2
	Capsules and capsule coatings for gastric residence dosage forms
Nupura Bhise, Watertown, MA (US); Erick Peeke, Cambridge, MA (US); Marlene Schwarz, Auburndale, MA (US); Megan Bishoff, Boston, MA (US); Sonia Holar, Boston, MA (US); and David Altreuter, Wayland, MA (US)
Assigned to LYNDRA THERAPEUTICS, INC., Watertown, MA (US)
Appl. No. 17/593,436
Filed by Lyndra Therapeutics, Inc., Watertown, MA (US)
PCT Filed Mar. 19, 2020, PCT No. PCT/US2020/023704 § 371(c)(1), (2) Date Sep. 17, 2021, PCT Pub. No. WO2020/191229, PCT Pub. Date Sep. 24, 2020.
Claims priority of provisional application 62/821,352, filed on Mar. 20, 2019.
Prior Publication US 2022/0160642 A1, May 26, 2022
Int. Cl. A61K 9/48 (2006.01)

CPC A61K 9/4891 (2013.01) [A61K 9/485 (2013.01); A61K 9/4866 (2013.01)]

20 Claims

1. A gastric residence dosage form comprising:

a gastric residence system in a folded configuration;

a sleeve surrounding at least a portion of the gastric residence system in the folded configuration, wherein the sleeve is configured to bind the gastric residence system into the folded configuration;

a capsule encapsulating the gastric residence system in the folded configuration; and

a coating on the capsule,

wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.